SaleJun 12, 2026, 07:16 AM
Rocket Pharma Sells Rare Pediatric PRV for $180M
AI Summary
Rocket Pharmaceuticals, Inc. announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. The PRV was granted following FDA approval of KRESLADI", a gene therapy for severe leukocyte adhesion deficiency-I (LAD-I). This non-dilutive transaction boosts the company's pro forma cash, cash equivalents, and investments to approximately $322.6 million, extending its operational runway into the second quarter of 2028.
Key Highlights
- Completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).
- Received gross proceeds of $180.0 million from the asset sale.
- The PRV was granted in connection with FDA approval of KRESLADI", a gene therapy for severe LAD-I.
- Pro forma cash, cash equivalents, and investments increased to approximately $322.6 million.
- Cash runway is now expected to fund operations into the second quarter of 2028.
- Prior cash, cash equivalents, and investments were $144.4 million as of March 31, 2026.
Price Impact
More from RCKT